Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 12

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 12
---
 Administration (“FDA”)
cleared the Company’s Investigational New Drug Application for Phase 1 clinical trial of its lead compound, CER-1236, in acute myelogenous
leukemia (“AML”), and in May 2025 announced the first patient was dosed with CER-1236 in a Phase 1/1b trial of AML. In June
2025, the Company announced the completion of the initial evaluation of the first patient in its Phase 1/1b trial without any dose-limiting
toxicity and dosed the second AML patient in July 2025. In September 2025, the Company announced that it had dosed the third patient in
the starting dose cohort of its Phase 1 clinical trial evaluating CER-1236 in AML.

We submitted a second Investigational
New Drug (“IND”) application for the investigation of CER-T cell therapy in NSCLC and ovarian cancer, which was accepted by
the FDA on March 27, 2025.

Nasdaq Delisting - On October 29, 2025,
the Company received the determination of the Nasdaq Hearings Panel (the “Panel”) to deny the Company’s request to continue
the listing of its shares of common stock on Nasdaq and that the trading in the Company’s securities would be suspended at the open
of trading on October 31, 2025. The Company submitted a request for review of the Panel’s decision by the Nasdaq Listing and Hearing
Review Council. On October 31, 2025, the Company’s shares of common stock commenced trading on the OTC Pink Sheets. The Company
has also commenced the process of seeking to trade its shares of common stock on the OTC Markets.

Reverse Stock Splits
– On January 8, 2025, the Company effected a reverse stock split of our shares of common stock at a ratio of 1-for-100 and on June
13, 2025, the Company effected a reverse stock split of our shares of common stock at a ratio of 1-for-20 (the “Reverse Stock Splits”).
The Company’s common stock continued to trade, prior to the Nasdaq Delisting, on Nasdaq on a post-split basis under the Company’s
existing trading symbol, “CERO”.

All of the Company’s
historical share and per share information related to issued and outstanding common stock and outstanding options and warrants exercisable
for common stock in these